CALC

CalciMedica, Inc. NASDAQ Listed Jun 14, 2023

Healthcare ·Biotechnology ·US · calcimedica.com

$0.63

Mkt Cap $9.9M

52w Low $0.46 2.5% of range 52w High $7.20

50d MA $0.63 200d MA $2.72

P/E (TTM) -0.3x

EV/EBITDA -4278.5x

P/B —

Debt/Equity -1.5x

ROE 445.1%

P/FCF -4664.9x

RSI (14) —

ATR (14) —

Beta 1.09

50d MA $0.63

200d MA $2.72

Avg Volume 420.1K

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

SIC Code

2834

CIK (SEC)

1534133

Phone

858-952-5500

505 Coast Boulevard South · La Jolla, CA 92037 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 3, 2026	AMC	-0.55	-0.32	+41.8%	0.58	+1.7%	+7.5%	+5.9%	+10.0%	+0.6%	-7.7%	—
Nov 12, 2025	AMC	-0.41	-0.39	+4.9%	3.34	-2.7%	-3.3%	-7.1%	+4.7%	-2.2%	+2.9%	—
Aug 12, 2025	AMC	-0.40	-0.40	+0.0%	2.48	+10.5%	-4.4%	+10.1%	+11.5%	+1.0%	-5.4%	—
May 14, 2025	AMC	-0.43	-0.36	+16.3%	1.91	+4.2%	+1.6%	+3.1%	-7.0%	+0.0%	-5.9%	—
Mar 27, 2025	AMC	-0.48	-0.34	+29.2%	2.07	+0.0%	-3.9%	-4.0%	+2.1%	-5.1%	-1.1%	—
Nov 13, 2024	AMC	-0.61	-0.50	+18.0%	3.40	-1.5%	-0.9%	-1.2%	+1.5%	-0.9%	+3.0%	—
Aug 12, 2024	AMC	-0.55	-0.52	+5.5%	4.68	-0.4%	-3.6%	+0.4%	-9.5%	+2.2%	+0.2%	—
May 13, 2024	AMC	-0.50	-0.43	+14.0%	5.20	-2.5%	+6.7%	-1.3%	-0.9%	+0.4%	-0.9%	—
Mar 28, 2024	AMC	-1.00	-0.23	+77.0%	4.16	+1.0%	-5.5%	+2.8%	+3.6%	+3.9%	-1.3%	—
Nov 9, 2023	AMC	-1.14	-0.82	+28.1%	3.15	+3.2%	+7.1%	+0.8%	-0.1%	+3.2%	-4.1%	—
Aug 10, 2023	AMC	-1.02	-1.11	-8.8%	3.28	+0.0%	-0.4%	-2.1%	+1.6%	-1.4%	+1.7%	—
May 12, 2023	AMC	-0.73	-23.43	-3109.6%	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 5	Oppenheimer	Maintains	Outperform → Outperform	—	$0.62	$0.61	-2.0%	+5.9%	+10.0%	+0.6%	-7.7%	+2.5%
Jan 29	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$1.25	$1.13	-9.6%	-18.4%	-11.8%	-25.6%	-9.1%	+8.4%
May 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.91	$1.99	+4.2%	+1.6%	+3.1%	-7.0%	+0.0%	-5.9%
Apr 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.91	$2.00	+4.7%	+2.1%	-5.1%	-1.1%	-0.5%	-0.5%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.20	$2.07	-5.9%	+3.2%	-6.2%	+3.3%	+1.8%	-3.1%
Nov 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.40	$3.35	-1.5%	-0.9%	-1.2%	+1.5%	-0.9%	+3.0%
Nov 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.51	$3.69	+5.1%	-0.3%	+1.1%	-1.1%	+0.0%	-0.9%
Aug 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.68	$4.66	-0.4%	-3.6%	+0.4%	-9.5%	+2.2%	+0.2%
Jul 10	Oppenheimer	Maintains	Outperform → Outperform	—	$4.44	$4.47	+0.7%	+3.2%	+3.1%	+3.6%	-1.6%	+1.5%
Jul 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.25	$4.30	+1.2%	+4.5%	+3.2%	+3.1%	+3.6%	-1.6%
Jun 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.66	$3.87	-17.0%	-32.4%	+25.7%	+7.3%	-5.6%	+6.2%
May 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.20	$5.07	-2.5%	+6.7%	-1.3%	-0.9%	+0.4%	-0.9%
Apr 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.16	$4.20	+1.0%	-5.5%	+2.8%	+3.6%	+3.9%	-1.3%
Apr 1	Oppenheimer	Maintains	Outperform → Outperform	—	$4.16	$4.20	+1.0%	-5.5%	+2.8%	+3.6%	+3.9%	-1.3%
Mar 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.50	$4.39	-2.4%	-3.6%	+0.5%	-9.6%	-8.6%	-5.8%
Feb 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.70	$5.75	+0.9%	-8.2%	-7.3%	-7.0%	-0.4%	-2.9%
Nov 13	Oppenheimer	Maintains	Outperform → Outperform	—	$3.37	$3.21	-4.8%	+0.8%	-0.0%	+3.2%	-4.1%	+3.6%
Jul 7	EF Hutton	Maintains	Buy → Buy	—	$4.00	$3.88	-3.0%	-3.5%	-4.4%	-2.4%	+7.1%	-4.0%

Data updated apr 24, 2026 11:43pm · Source: massive.com